Julie Brooks Net Worth

The estimated Net Worth of Julie Brooks is at least $94.7 Thousand dollars as of 28 July 2014. Julie Brooks owns over 1,122 units of Veracyte Inc stock worth over $94,659 and over the last 11 years Julie sold VCYT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Julie Brooks VCYT stock SEC Form 4 insiders trading

Julie has made over 2 trades of the Veracyte Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Julie bought 1,122 units of VCYT stock worth $16,482 on 28 July 2014.

The largest trade Julie's ever made was buying 2,000 units of Veracyte Inc stock on 21 July 2014 worth over $28,360. On average, Julie trades about 390 units every 1 days since 2014. As of 28 July 2014 Julie still owns at least 3,122 units of Veracyte Inc stock.

You can see the complete history of Julie Brooks stock trades at the bottom of the page.

What's Julie Brooks's mailing address?

Julie's mailing address filed with the SEC is VERACYTE, INC., 7000 SHORELINE COURT, SUITE 250, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Veracyte Inc

Over the last 11 years, insiders at Veracyte Inc have traded over $201,983,044 worth of Veracyte Inc stock and bought 75,122 units worth $1,149,322 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Nicole Vitullo, and Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of $804,905. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth $163,165.

What does Veracyte Inc do?

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .

Complete history of Julie Brooks stock trades at Veracyte Inc

Veracyte Inc executives and stock owners

Veracyte Inc executives and other stock owners filed with the SEC include:

• Bonnie H. Anderson,
  Co-Founder & Exec. Chairwoman
• Dr. Giulia C. Kennedy Ph.D.,
  Global Chief Scientific Officer & Chief Medical Officer
• John Walter Hanna Jr.,
  Chief Commercial Officer and GM of Endocrinology, Breast Cancer & Lymphoma
• Rebecca Chambers,
  Exec. VP & CFO
• Dr. Tina S. Nova Ph.D.,
  Pres of CLIA U.S. Bus.
• Annie McGuire,
  Sr. VP & Gen. Counsel
• Jonathan Wygant,
  VP & Chief Accounting Officer
• Robert Brainin,
  Exec. VP & Chief Bus. Officer
• Dr. Alfred Bowie Jr., Ph.D.,
  VP of Corp. & Bus. Devel.
• Tracy Morris,
  VP of Corp. Communications & Investor Relations
• William W. Zondler,
  Sr. VP & Chief Information Officer
• Beverly Jane Alley CPA,
  VP, Corp. Controller & Principal Accounting Officer
• Marc A. Stapley,
  CEO & Director
• Marc Stapley,
  Chief Executive Officer
• Rebecca Chambers,
  Chief Financial Officer
• Karin Eastham,
  Director
• Brian G Atwood,
  Director
• Keith Kennedy,
  COO / CFO
• Christopher M Hall,
  Chief Commercial Officer
• Perkins Caufield & Byers Xi...,
  
• John L Bishop,
  Director
• Evan/ Fa Jones,
  Director
• Fred E Cohen,
  Director
• Shelly D Guyer,
  Chief Financial Officer
• Robert S Epstein,
  Director
• Kevin K Gordon,
  Director
• Muna Bhanji,
  Director
• Julie Brooks,
  EVP,General Counsel,Secretary
• Jesse I Treu,
  Director
• Giulia C Kennedy,
  Chief Scientific & Med Officer
• Bonnie H Anderson,
  Director
• Ventures Iii, Llc Versant V...,
  
• Viii Associates, L.P. Dp,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Brook H Byers,
  Director
• Brian K Halak,
  10% owner
• Duncan Thomas Powell,
  Principal Accounting Officer
• Partners Viii, L.P.Blair Ja...,
  
• Samuel D Colella,
  Director
• Brian H Dovey,
  10% owner
• Nicole Vitullo,
  10% owner
• Partners Viii, L.P. Domain,
  10% owner
• James C Blair,
  10% owner
• John Walter Jr Hanna,
  Chief Commercial Officer
• Mark Ho,
  
• Iii James H Erlinger,
  
• Jens Holstein,
  Director
• John Leite,
  Chief Commercial Officer-CLIA
• Beverly Jane Alley,
  VP, Corporate Controller
• David Brent Shafer,
  Director
• Thomas F. Miller,
  Director
• Tina Susan Nova,
  President, CLIA U.S.
• Annie Mc Guire,
  SVP, General Counsel
• Eliav Barr,
  Director
• Jonathan Wygant,
  VP, Chief Accounting Officer
• Phillip G. Febbo,
  Chief Scientific & Med Officer